Here are 1-3 brief analogies for Inhibikase Therapeutics (IKT):

• Vertex Pharmaceuticals, but for Parkinson's disease.

• A clinical-stage Biogen, singularly focused on Parkinson's disease.

• A biotech like Biohaven Pharmaceuticals, but specializing in Parkinson's disease and its related gastrointestinal complications.

• IkT-148009: A small molecule Abelson tyrosine kinase inhibitor for treating Parkinson's Disease and related gastrointestinal complications.
• IkT-001Pro: A prodrug of Imatinib in preclinical development to treat blood and stomach cancers while minimizing gastrointestinal side effects.
• Research Programs: Ongoing research and development initiatives focused on various other neurological diseases.

Inhibikase Therapeutics (IKT) is a clinical-stage pharmaceutical company. According to the provided background, the company is focused on the research and development of its product candidates, IkT-148009 and IkT-001Pro, which are in clinical or preclinical development. As a clinical-stage company, its products have not yet been approved for sale or commercialized.

Therefore, Inhibikase Therapeutics does not currently have major commercial customers who purchase its products or services.

Mark Iwicki, Chief Executive Officer

Mr. Iwicki joined Inhibikase Therapeutics as CEO in February 2025, succeeding founder Milton H. Werner. He brings over 30 years of biopharmaceutical industry experience, including prior Chief Executive Officer roles at KALA BIO, Civitas Therapeutics, Sunovion Pharmaceuticals Inc., and Blend Therapeutics. He also served as President and Chief Operating Officer at Sepracor. Mr. Iwicki currently serves as Chair of the board of directors of KALA BIO and on the boards of Nimbus, Akero Therapeutics, Third Harmonic Bio, Q32 Bio, and Merus.

David McIntyre, Chief Financial Officer

Mr. McIntyre was appointed Chief Financial Officer of Inhibikase Therapeutics, effective April 14, 2025. He has over two decades of executive experience in the life sciences sector, holding various C-suite roles at both public and private biotech and medical device companies, including Anthos Therapeutics, HeartWare International, AVITA Medical, Tessa Therapeutics, and Braeburn. Prior to joining Inhibikase, he spent nearly a decade as a Partner at Apple Tree Partners, a multi-billion-dollar life sciences venture capital and growth equity fund. His background also includes practicing as a senior attorney specializing in mergers and acquisitions, initial public offerings, and corporate law at Baker McKenzie and KPMG.

Chris Cabell, MD MHS FACC, President, Head of Research and Development, and Chief Medical Officer

Dr. Cabell serves as President, Head of Research and Development, and Chief Medical Officer of Inhibikase Therapeutics. He previously held the position of Chief Executive Officer of CorHepta Pharmaceuticals, which was acquired by Inhibikase, and served as Head of Clinical Development and Chief Medical Officer at Zura Bio and Emergent BioSolutions.

John Adams, PhD, Chief Scientific Officer

Dr. Adams is the Chief Scientific Officer at Inhibikase. He co-founded CorHepta Pharmaceuticals, and previously served as Senior Vice President of Discovery Biology at Iambic Therapeutics, Senior Vice President of Translational Science at Reneo Pharmaceuticals, and Head of Research at Arena Pharmaceuticals.

Chad Orevillo, Executive Vice President, Head of Operations

Mr. Orevillo has over 30 years of experience in pharmaceutical clinical development, operations, and program management. Before joining Inhibikase, he co-founded and served as Executive Vice President and Head of Operations for Longboard Pharmaceuticals. He also held the role of Vice President and Head of Clinical Operations at Arena Pharmaceuticals and management positions at Merck, Pharmacia, Pfizer, Novartis, Pearl Therapeutics, and AstraZeneca.

The key risks for Inhibikase Therapeutics (IKT), a clinical-stage pharmaceutical company, primarily revolve around the inherent challenges of drug development and financial sustainability.

1. Clinical Trial Failure and Regulatory Approval: As a clinical-stage company, Inhibikase Therapeutics' success hinges on the successful progression of its drug candidates through rigorous clinical trials and ultimately, obtaining regulatory approval. This risk has recently materialized with the company's decision to suspend further development of risvodetinib (formerly IkT-148009) for Parkinson's disease due to underwhelming efficacy findings in a Phase II trial, despite meeting safety and tolerability endpoints. The company has since pivoted its primary focus to IkT-001Pro for pulmonary arterial hypertension (PAH), making its successful development and regulatory pathway critical for the company's future.

2. Funding and Financial Instability: Inhibikase Therapeutics is currently unprofitable and is not projected to achieve profitability within the next three years, relying heavily on external financing to fund its extensive research and development activities. Reports indicate significant cash outflows and ongoing net losses, raising concerns about its capital adequacy. The company's current cash reserves have been noted as insufficient to fund late-stage clinical trials, necessitating the securing of substantial additional funding, which has led to shareholder dilution in the past.

3. Intense Competition: The pharmaceutical industry, particularly in the neurodegenerative and cardiopulmonary disease spaces where Inhibikase Therapeutics operates, is highly competitive. The company faces competition from numerous established pharmaceutical companies and emerging biotechs developing treatments for similar conditions. This competitive landscape could impact the market potential and commercial viability of any approved products.

Inhibikase Therapeutics (IKT) develops therapeutics for Parkinson's Disease (PD) and related disorders. The company's main products, IkT-148009 and IkT-001Pro, target several significant addressable markets.

IkT-148009 (Parkinson's Disease and related disorders)

IkT-148009 is being developed for Parkinson's Disease (PD), as well as associated gastrointestinal complications like swallowing difficulties (dysphagia), neurogenic constipation, and Multiple System Atrophy (MSA).

• Parkinson's Disease Treatment Market:

  • Globally, the Parkinson's Disease therapeutics market was valued at approximately USD 6.2 billion in 2024 and is projected to reach USD 13.3 billion by 2034, with a compound annual growth rate (CAGR) of 8.1% from 2025 to 2034. Another estimate places the global market at USD 7.49 billion in 2025, anticipated to grow to USD 17.57 billion by 2035 at a CAGR of 8.9%.
  • In the U.S. alone, the Parkinson's Disease market was approximately USD 1.883 billion in 2023. North America is a dominant region, holding an estimated 39.5% of the global market share in 2024.

• Dysphagia Management Market:

  • The global dysphagia management market was valued at USD 4.71 billion in 2024 and is projected to increase to USD 8.64 billion by 2034, exhibiting a CAGR of 6.27% from 2025 to 2034. Another report states a global market size of USD 5.2917 billion in 2025, expected to reach USD 8.8902 billion by 2033 with a CAGR of 6.70%.
  • North America held the largest share of the dysphagia management market, accounting for 48% in 2024. The U.S. market specifically was valued at USD 1.58 billion in 2024 and is projected to reach approximately USD 2.96 billion by 2034, with a CAGR of 6.48% from 2025 to 2034.

• Neurogenic Constipation (part of the broader Constipation Treatment Market):

  • The global constipation treatment drugs market reached USD 8.4 billion in 2024 and is projected to grow to USD 13.3 billion by 2033, at a CAGR of 5.2% from 2025 to 2033. Another source indicates the global constipation treatment market was valued at USD 19.31 billion in 2024 and is poised to grow to USD 32.9 billion by 2033, at a CAGR of 6.1% from 2026 to 2033.
  • North America represents the largest regional market for constipation treatment drugs, with approximately USD 3.1 billion in revenue in 2024.

• Multiple System Atrophy (MSA) Therapeutics Market:

  • Globally, the Multiple System Atrophy (MSA) therapeutics market is estimated to be valued at USD 149.6 million in 2025 and is projected to reach USD 230.2 million by 2035, growing at a CAGR of 4.4% over the forecast period. Another report estimates the global market at USD 380 million in 2024, expanding to USD 625 million by 2030 with a CAGR of 8.6%.
  • In the U.S., the MSA market was estimated at USD 159.6 million in 2024 and is projected to reach approximately USD 246.5 million by 2030, with a 7.5% CAGR. North America accounts for 45.3% of the market share in 2025.

IkT-001Pro (Blood and Stomach Cancers)

IkT-001Pro is a prodrug of imatinib, in preclinical development for blood and stomach cancers, specifically chronic myelogenous leukemia.

• Blood Cancer (Hematologic Malignancies) Treatment Market:

  • The global blood cancer drug market was valued at USD 41.94 billion in 2024 and is forecast to reach USD 68.51 billion by 2035, growing at a CAGR of 4.56% from 2025 to 2035. The broader hematologic malignancies market size reached USD 65.1 billion in 2024 and is expected to reach USD 129.5 billion by 2033, with a CAGR of 7.55% during 2025-2033.
  • North America is the largest market for blood cancer drugs, accounting for approximately 45% of the global market share.

• Stomach Cancer Treatment Market:

  • The global stomach cancer treatment market size was valued at USD 4.7 billion in 2023 and is estimated to grow at a 13.5% CAGR from 2024 to 2032, reaching USD 14.4 billion by 2032. Another estimate values the global market at USD 5.3696 billion in 2024, projected to reach USD 11.1949 billion by 2030 with a CAGR of 12.5% from 2025 to 2030.
  • The U.S. stomach cancer treatment market is projected to reach USD 1.4 billion by 2026. In 2024, the U.S. market dominated North America, holding a 90.5% revenue share for stomach cancer treatment.

1. Advancement and Potential Commercialization of IkT-001Pro for Pulmonary Arterial Hypertension (PAH): The primary driver of future revenue growth is the successful progression and eventual commercialization of IkT-001Pro, a prodrug of imatinib mesylate, for the treatment of Pulmonary Arterial Hypertension. The company expects to initiate a Phase 2b clinical study (IMPROVE-PAH) in the fourth quarter of 2025, following receipt of IND-clearance from the FDA. PAH represents a significant global market, estimated at $7.7 billion annually, and successful clinical development and market entry would generate substantial revenue for Inhibikase Therapeutics.
2. Strategic Partnerships and Licensing Agreements: As a clinical-stage biotechnology company, future revenue growth is also expected to be driven by strategic collaborations and licensing agreements. Positive results from ongoing or upcoming clinical trials, particularly for IkT-001Pro, could attract pharmaceutical partners interested in co-developing, co-commercializing, or licensing the drug candidates. Such agreements typically involve upfront payments, milestone payments upon achieving specific development or regulatory goals, and potential royalties on future sales, providing new revenue streams for Inhibikase Therapeutics.
3. Expansion of IkT-001Pro into Additional Indications: Beyond Pulmonary Arterial Hypertension, IkT-001Pro is also in preclinical development for the treatment of blood and stomach cancers. Progress in these additional indications, including the initiation of clinical trials, would expand the potential market for IkT-001Pro, thereby driving further revenue growth as these programs advance towards commercialization.

Share Issuance

• In November 2025, Inhibikase Therapeutics priced an underwritten public offering, aiming to raise approximately $100.0 million in gross proceeds. This offering included 46,091,739 shares of common stock at $1.45 each and pre-funded warrants to purchase 22,873,779 shares at $1.449 each. Underwriters were also granted a 30-day option to purchase up to an additional 10,344,827 shares.
• In October 2024, the company completed a private placement, raising approximately $110 million from the issuance and sale of common stock and accompanying warrants. This financing had a potential to reach approximately $275 million upon the full cash exercise of the warrants.
• On January 3, 2025, Inhibikase stockholders approved an amendment to increase the number of authorized shares of common stock from 100,000,000 to 500,000,000 shares. Additionally, they approved an increase of 27,453,993 shares reserved for issuance under the company's 2020 Equity Incentive Plan.

Inbound Investments

• In October 2024, Inhibikase Therapeutics closed a private placement of approximately $110 million from the issuance and sale of common stock and accompanying warrants, with the potential for aggregate financing of up to $275 million upon the full cash exercise of the warrants. This investment was supported by "top tier dedicated healthcare investment funds".
• Around October 2024, Inhibikase Therapeutics anticipated receiving $109.98 million in funding from a group of investors.

Outbound Investments

• In February 2025, Inhibikase Therapeutics acquired CorHepta Pharmaceuticals, Inc. for $14.8 million. This acquisition led to a non-cash write-off of in-process research and development of $7.4 million and $1.8 million in stock-based compensation expense during the first nine months of 2025.